Genetic engineering drugs, antibody engineering drugs, blood products drugs, and vaccines are common biological drugs. De novo design of antibodies binding specific epitopes could greatly accelerate discovery of therapeutics as compared to conventional immunization or synthetic library selection strategies. Computational approaches have the potential to dramatically reduce the resources required for antibody discovery while increasing success rates for challenging targets. Our AI-driven platform utilizes molecular simulation technologies to provide antibody De novo design.
Powerful drug-like antibody bio-computation (cloud/super-computing).
Modular antibody parts (MAPs) database.
Potent software platforms.
Therapeutic antibodies validation platform.
|Constructing antibody library
|Final optimization of structure Predict anti-antibody complex structure
Antibody sequence report.
Structure analysis of specific targets (antigens).
Molecular simulation and molecular dynamics ordering.
Computational ordering of antibody library (human or specific species).
Leads with the great affinity.
Antibody library or the synthesized leads antibodies.
Design anti-HIV and antimicrobial peptides.
Design epitope mimics for vaccination.
Design influenza inhibitors.
Tech Trends in Artificial Intelligence What's up, what's down, what lies ahead, only found in MedAI!